Avalo Therapeutics (AVTX) Stock Forecast, Price Target & Predictions
AVTX Stock Forecast
Avalo Therapeutics stock forecast is as follows: an average price target of $35.00 (represents a 281.26% upside from AVTX’s last price of $9.18) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
AVTX Price Target
The average price target for Avalo Therapeutics (AVTX) is $35.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $35.00. This represents a potential 281.26% upside from AVTX's last price of $9.18.
AVTX Analyst Ratings
According to 3 Wall Street analysts, Avalo Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for AVTX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Avalo Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 16, 2024 | Leland Gershell | Oppenheimer | $35.00 | $15.24 | 129.66% | 281.26% |
The latest Avalo Therapeutics stock forecast, released on Apr 16, 2024 by Leland Gershell from Oppenheimer, set a price target of $35.00, which represents a 129.66% increase from the stock price at the time of the forecast ($15.24), and a 281.26% increase from AVTX last price ($9.18).
Avalo Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $35.00 |
| Last Closing Price | $9.18 | $9.18 | $9.18 |
| Upside/Downside | -100.00% | -100.00% | 281.26% |
In the current month, the average price target of Avalo Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avalo Therapeutics's last price of $9.18. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Apr 16, 2024 | Oppenheimer | - | Outperform | Upgrade |
| Jun 27, 2023 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Jun 27, 2023 | RBC Capital | - | Sector Perform | Downgrade |
| Feb 08, 2023 | Jefferies | - | Underperform | Downgrade |
Avalo Therapeutics's last stock rating was published by Oppenheimer on Aug 15, 2024. The company gave AVTX a "Outperform" rating, the same as its previous rate.
Avalo Therapeutics Financial Forecast
Avalo Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $236.00K | $643.00K | $475.00K | $896.00K | $14.95M | $1.03M | $1.17M | $219.00K | $1.35M | $3.35M | $473.00K | $1.11M | $1.34M | $2.75M | $-8.72M | $5.61M | $4.45M | $5.41M | $384.21K | $650.49K |
| Avg Forecast | - | - | - | - | $300.00K | $300.00K | $300.00K | $300.00K | $300.00K | $1.00M | $1.00M | $1.00M | $3.61M | $1.26M | $1.19M | $645.50K | $1.02M | $1.12M | $333.33K | $539.33K | $1.50M | $2.25M | $1.84M | $4.95M | $5.34M | $4.71M | $3.17M | $748.19K | $698.08K |
| High Forecast | - | - | - | - | $300.00K | $300.00K | $300.00K | $300.00K | $300.00K | $1.00M | $1.00M | $1.00M | $3.61M | $1.26M | $1.19M | $645.50K | $1.02M | $1.12M | $333.33K | $539.33K | $1.50M | $2.25M | $1.84M | $4.95M | $5.34M | $4.71M | $3.81M | $897.83K | $837.70K |
| Low Forecast | - | - | - | - | $300.00K | $300.00K | $300.00K | $300.00K | $300.00K | $1.00M | $1.00M | $1.00M | $3.61M | $1.26M | $1.19M | $645.50K | $1.02M | $1.12M | $333.33K | $539.33K | $1.50M | $2.25M | $1.84M | $4.95M | $5.34M | $4.71M | $2.54M | $598.55K | $558.47K |
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.24% | 0.64% | 0.47% | 0.25% | 11.88% | 0.87% | 1.82% | 0.22% | 1.21% | 10.07% | 0.88% | 0.74% | 0.59% | 1.49% | -1.76% | 1.05% | 0.95% | 1.71% | 0.51% | 0.93% |
Avalo Therapeutics's average Quarter revenue forecast for Dec 23 based on 1 analysts is $300.00K, with a low forecast of $300.00K, and a high forecast of $300.00K. AVTX's average Quarter revenue forecast represents a 27.12% increase compared to the company's last Quarter revenue of $236.00K (Sep 23).
Avalo Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-3.75M | $-7.15M | $-8.82M | $-8.82M | $4.09M | $-11.80M | $-20.79M | $-20.10M | $-15.95M | $-17.09M | $-30.20M | $-13.03M | $-13.30M | $-22.81M | $2.91M | $-3.04M | $-5.25M | $-6.40M | $-2.01M | $-3.64M |
| Avg Forecast | - | - | - | - | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-1.00M | $-1.00M | $-1.00M | $-3.61M | $-19.39M | $-1.19M | $-11.75M | $-1.02M | $-1.12M | $-333.33K | $-21.77M | $-1.50M | $-2.25M | $-31.95M | $-4.95M | $-5.34M | $-4.71M | $-7.35M | $-2.62M | $-3.76M |
| High Forecast | - | - | - | - | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-1.00M | $-1.00M | $-1.00M | $-3.61M | $-15.51M | $-1.19M | $-9.40M | $-1.02M | $-1.12M | $-333.33K | $-17.42M | $-1.50M | $-2.25M | $-25.56M | $-4.95M | $-5.34M | $-4.71M | $-5.88M | $-2.09M | $-3.01M |
| Low Forecast | - | - | - | - | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-1.00M | $-1.00M | $-1.00M | $-3.61M | $-23.27M | $-1.19M | $-14.10M | $-1.02M | $-1.12M | $-333.33K | $-26.13M | $-1.50M | $-2.25M | $-38.34M | $-4.95M | $-5.34M | $-4.71M | $-8.82M | $-3.14M | $-4.51M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.75% | 7.15% | 8.82% | 2.44% | -0.21% | 9.94% | 1.77% | 19.75% | 14.29% | 51.26% | 1.39% | 8.69% | 5.91% | 0.71% | -0.59% | 0.57% | 1.12% | 0.87% | 0.77% | 0.97% |
0 analysts predict AVTX's average Quarter EBITDA for Dec 22 to be $-3.61M, with a high of $-3.61M and a low of $-3.61M. This is -188.17% lower than Avalo Therapeutics's previous annual EBITDA (Sep 22) of $4.09M.
Avalo Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $-5.23M | - | $-9.96M | $-9.81M | $3.19M | $-12.99M | $-22.05M | $-19.13M | $-17.39M | $-17.11M | $-30.68M | $-13.46M | $-13.28M | $-21.12M | $1.62M | $-4.02M | $-6.22M | $-7.45M | $-1.96M | $-3.52M |
| Avg Forecast | $-12.63M | $-12.78M | $-12.32M | $-12.47M | $-12.25M | $-11.10M | $-51.28M | $-9.03M | $-36.74M | $-2.02B | $-1.47B | $-1.78B | $-1.35B | $-21.15M | $-3.25B | $-11.20M | $-3.26B | $-3.70B | $-3.67B | $-22.11M | $-2.09B | $-2.31B | $-29.56M | $-2.57B | $-3.09B | $-3.23B | $-8.85M | $-2.62M | $-3.76M |
| High Forecast | $-12.63M | $-12.78M | $-12.32M | $-12.47M | $-12.25M | $-11.10M | $-51.28M | $-9.03M | $-36.74M | $-2.02B | $-1.47B | $-1.78B | $-1.35B | $-16.92M | $-3.25B | $-8.96M | $-3.26B | $-3.70B | $-3.67B | $-17.68M | $-2.09B | $-2.31B | $-23.65M | $-2.57B | $-3.09B | $-3.23B | $-7.08M | $-2.10M | $-3.01M |
| Low Forecast | $-12.63M | $-12.78M | $-12.32M | $-12.47M | $-12.25M | $-11.10M | $-51.28M | $-9.03M | $-36.74M | $-2.02B | $-1.47B | $-1.78B | $-1.35B | $-25.38M | $-3.25B | $-13.43M | $-3.26B | $-3.70B | $-3.67B | $-26.53M | $-2.09B | $-2.31B | $-35.48M | $-2.57B | $-3.09B | $-3.23B | $-10.62M | $-3.15M | $-4.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | - | 0.01% | 0.01% | -0.15% | 0.00% | 1.97% | 0.01% | 0.00% | 0.00% | 1.39% | 0.01% | 0.01% | 0.71% | -0.00% | 0.00% | 0.00% | 0.84% | 0.75% | 0.94% |
Avalo Therapeutics's average Quarter net income forecast for Dec 22 is $-1.35B, with a range of $-1.35B to $-1.35B. AVTX's average Quarter net income forecast represents a -42298.66% decrease compared to the company's last Quarter net income of $3.19M (Sep 22).
Avalo Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $2.49M | $2.43M | $2.71M | $2.96M | $3.28M | $2.78M | $11.68M | $5.98M | $5.93M | $7.40M | $5.35M | $5.04M | $6.75M | $3.35M | $-4.85M | $5.31M | $5.32M | $5.83M | $1.33M | $1.64M |
| Avg Forecast | - | - | - | - | $944.28K | $944.28K | $944.28K | $944.28K | $944.28K | $3.15M | $3.15M | $3.15M | $11.36M | $3.96M | $3.73M | $2.03M | $3.20M | $3.51M | $1.05M | $1.70M | $4.72M | $7.08M | $5.80M | $15.58M | $16.79M | $14.82M | $9.98M | $2.36M | $2.20M |
| High Forecast | - | - | - | - | $944.28K | $944.28K | $944.28K | $944.28K | $944.28K | $3.15M | $3.15M | $3.15M | $11.36M | $3.96M | $3.73M | $2.03M | $3.20M | $3.51M | $1.05M | $1.70M | $4.72M | $7.08M | $5.80M | $15.58M | $16.79M | $14.82M | $11.98M | $2.83M | $2.64M |
| Low Forecast | - | - | - | - | $944.28K | $944.28K | $944.28K | $944.28K | $944.28K | $3.15M | $3.15M | $3.15M | $11.36M | $3.96M | $3.73M | $2.03M | $3.20M | $3.51M | $1.05M | $1.70M | $4.72M | $7.08M | $5.80M | $15.58M | $16.79M | $14.82M | $7.98M | $1.88M | $1.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.79% | 0.77% | 0.86% | 0.26% | 0.83% | 0.75% | 5.75% | 1.87% | 1.69% | 7.06% | 3.15% | 1.07% | 0.95% | 0.58% | -0.31% | 0.32% | 0.36% | 0.58% | 0.56% | 0.74% |
Avalo Therapeutics's average Quarter SG&A projection for Dec 23 is $944.28K, based on 1 Wall Street analysts, with a range of $944.28K to $944.28K. The forecast indicates a -62.08% fall compared to AVTX last annual SG&A of $2.49M (Sep 23).
Avalo Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.11 | $-0.59 | $-0.85 | $-1.16 | $0.34 | $-1.38 | $-2.35 | $-2.28 | $-2.04 | $-2.16 | $-3.84 | $-2.04 | $-2.28 | $-4.08 | $0.35 | $-0.84 | $-1.32 | $-1.56 | $-2.28 | $-4.92 |
| Avg Forecast | $-1.65 | $-1.67 | $-1.61 | $-1.63 | $-1.60 | $-1.45 | $-6.70 | $-1.18 | $-4.80 | $-264.00 | $-192.00 | $-232.80 | $-176.00 | $-210.60 | $-424.80 | $-360.00 | $-426.24 | $-483.84 | $-480.00 | $-480.00 | $-273.60 | $-302.40 | $-297.60 | $-336.00 | $-403.20 | $-422.40 | $-2.28 | $-5.94 | $-5.64 |
| High Forecast | $-1.65 | $-1.67 | $-1.61 | $-1.63 | $-1.60 | $-1.45 | $-6.70 | $-1.18 | $-4.80 | $-264.00 | $-192.00 | $-232.80 | $-176.00 | $-210.60 | $-424.80 | $-360.00 | $-426.24 | $-483.84 | $-480.00 | $-480.00 | $-273.60 | $-302.40 | $-297.60 | $-336.00 | $-403.20 | $-422.40 | $-1.82 | $-4.75 | $-4.51 |
| Low Forecast | $-1.65 | $-1.67 | $-1.61 | $-1.63 | $-1.60 | $-1.45 | $-6.70 | $-1.18 | $-4.80 | $-264.00 | $-192.00 | $-232.80 | $-176.00 | $-210.60 | $-424.80 | $-360.00 | $-426.24 | $-483.84 | $-480.00 | $-480.00 | $-273.60 | $-302.40 | $-297.60 | $-336.00 | $-403.20 | $-422.40 | $-2.74 | $-7.13 | $-6.77 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.01% | -0.00% | 0.00% | 0.01% | 0.01% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | -0.00% | 0.00% | 0.00% | 0.68% | 0.38% | 0.87% |
According to 0 Wall Street analysts, Avalo Therapeutics's projected average Quarter EPS for Dec 22 is $-176.00, with a low estimate of $-176.00 and a high estimate of $-176.00. This represents a -51864.71% decrease compared to AVTX previous annual EPS of $0.34 (Sep 22).
Avalo Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| IPSC | Century Therapeutics | $1.65 | $20.00 | 1112.12% | Buy |
| ALXO | ALX Oncology | $2.14 | $24.50 | 1044.86% | Buy |
| BNOX | Bionomics | $0.64 | $6.00 | 837.50% | Buy |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| MOLN | Molecular Partners | $4.84 | $29.00 | 499.17% | Buy |
| AVTX | Avalo Therapeutics | $9.18 | $35.00 | 281.26% | Hold |
| ANEB | Anebulo Pharmaceuticals | $2.00 | $6.00 | 200.00% | Buy |
| ACRV | Acrivon Therapeutics | $7.56 | $22.00 | 191.01% | Buy |
| MLYS | Mineralys Therapeutics | $11.69 | $30.00 | 156.63% | Buy |
| EWTX | Edgewise Therapeutics | $19.07 | $48.00 | 151.70% | Buy |
| GPCR | Structure Therapeutics | $38.26 | $86.00 | 124.78% | Buy |
| CGEM | Cullinan Oncology | $17.23 | $32.00 | 85.72% | Buy |
| CCCC | C4 Therapeutics | $6.38 | $11.33 | 77.59% | Hold |
| ANAB | AnaptysBio | $36.57 | $36.33 | -0.66% | Buy |
| ACLX | Arcellx | $80.55 | $61.00 | -24.27% | Buy |
AVTX Forecast FAQ
Is Avalo Therapeutics a good buy?
No, according to 3 Wall Street analysts, Avalo Therapeutics (AVTX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of AVTX's total ratings.
What is AVTX's price target?
Avalo Therapeutics (AVTX) average price target is $35 with a range of $35 to $35, implying a 281.26% from its last price of $9.18. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Avalo Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AVTX stock, the company can go up by 281.26% (from the last price of $9.18 to the average price target of $35), up by 281.26% based on the highest stock price target, and up by 281.26% based on the lowest stock price target.
Can Avalo Therapeutics stock reach $14?
AVTX's average twelve months analyst stock price target of $35 supports the claim that Avalo Therapeutics can reach $14 in the near future.
What are Avalo Therapeutics's analysts' financial forecasts?
Avalo Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.2M (high $1.2M, low $1.2M), average EBITDA is $-1.2M (high $-1.2M, low $-1.2M), average net income is $-83.651M (high $-83.651M, low $-83.651M), average SG&A $3.78M (high $3.78M, low $3.78M), and average EPS is $-10.93 (high $-10.93, low $-10.93). AVTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-50.206M (high $-50.206M, low $-50.206M), average SG&A $0 (high $0, low $0), and average EPS is $-6.56 (high $-6.56, low $-6.56).
Did the AVTX's actual financial results beat the analysts' financial forecasts?
Based on Avalo Therapeutics's last annual report (Dec 2023), the company's revenue was $1.41M, which missed the average analysts forecast of $3.3M by -57.33%. Apple's EBITDA was $-27.867M, beating the average prediction of $-3.3M by 744.45%. The company's net income was $-31.544M, missing the average estimation of $-5.308B by -99.41%. Apple's SG&A was $10.3M, missing the average forecast of $10.39M by -0.84%. Lastly, the company's EPS was $-114, missing the average prediction of $-694 by -83.56%. In terms of the last quarterly report (Sep 2023), Avalo Therapeutics's revenue was $236K, missing the average analysts' forecast of $1M by -76.40%. The company's EBITDA was $-3.75M, beating the average prediction of $-1M by 275.00%. Avalo Therapeutics's net income was $-5.228M, missing the average estimation of $-2.02B by -99.74%. The company's SG&A was $2.49M, missing the average forecast of $3.15M by -20.89%. Lastly, the company's EPS was $-0.11, missing the average prediction of $-264 by -99.96%